Osaka Medical College, Fukui Tateami Co., Ltd. and Teijin Limited announced that the alliance has launched a clinical trial of their newly developed patch material, OFT-G1, for cardiovascular surgery and the first surgery using the OFT-G1 was successfully performed.
Tokyo, Japan, June 26, 2019--- Osaka Medical College, Fukui Tateami Co., Ltd. and Teijin Limited announced today that the alliance has launched a clinical trial of their newly developed patch material, OFT-G1 (provisional name), for cardiovascular surgery and the first surgery using the OFT-G1 was successfully performed.
The OFT-G1 is revolutionary designed by surgical expertise in cardiovascular surgery of Osaka Medical College, pioneering warp-knitting technology of Fukui Tateami, and advanced polymer-application technology of Teijin. The joint development of the OFT-G1 has been supported by a special program designed to facilitate collaborations between medical academia and industrial field promoted by the Japan Agency for Medical Research and Development (AMED). The Japan Ministry of Health, Labor and Welfare has designated the OFT-G1 as a SAKIGAKE product, which afford the OFT-G1 various incentives to speed up the approval process for clinical use.
Many kinds of cardiovascular patches have been widely used for surgical corrections, such as closure of defects in the hearts and enlargement of narrow vessels. However, previous products have many drawbacks and often cause reoperation in the long term. While the OFT-G1 reveals its strong and elastic structure as the previous products, the OFT is the only product in which the absorbable portion is naturally replaced with the patients’ own tissue after implantation. This is why the OFT-G1 is ideal for cardiovascular surgery especially in children who need the implanted material could expand in size along with their body growth. Therefore, the OFT-G1 is expected to avoid reoperation causing physical, mental, and economic burdens on patients and their families.
The first surgical implantation of the OFT-G1 in human was performed on 4-month-old infant who needed a patch closure of a large ventricular septal defect. The patient recovered and discharged from hospital uneventfully and currently receives outpatient follow-up.
Osaka Medical College, Fukui Tateami, and Teijin are continuing the clinical trial to prove the clinical effectiveness and safety of the OFT-G1, an approved cardiovascular patch as quickly as possible in Japan followed by other countries worldwide. They will also continue any efforts in expanding product development to contribute bright future for patients with cardiovascular diseases.
About Osaka Medical College
Established in 1927 as Japan’s first five-year higher school of medicine, Osaka Medical College celebrated its 90th anniversary in 2017 having produced more than 9,000 skilled physicians. The College’s nursing education program has a similar history, and has trained more than 4,500 nurses.
URL: https://www.osaka-med.ac.jp/
Press Contact
Center for Research & Development
Administrative officer
Osaka Medical College
+81 72 684 6333
About Fukui Tateami Co., Ltd.
Fukui Tateami is a warp knitted fabric manufacturing company located in Fukui, Japan, with 90 employees and more. Our products encompass a wide spectrum of applications, such as fashionable apparel, active sportswear, automotive interiors, industrial materials, household textiles. With over 75 years of extensive experience and advanced technology, Fukui Tateami has entered the medical field. It posted sales of JPY3.4 billion (USD 31 million) and total assets of JPY 3.0 billion (USD 27 million) in the fiscal year ending March 31, 2019.
Please visit www.fukutate.co.jp/en/
Press Contact
General Affairs
Fukui Tateami Co., Ltd.
+81 776 54 3602
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the areas of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Its main fields of operation are high-performance fibers such as aramid, carbon fibers & composites, healthcare, films, resin & plastic processing, polyester fibers, products converting and IT. The group has over 170 companies and around 20,000 employees spread out over 20 countries worldwide. It posted consolidated sales of JPY888.6 billion (USD 8.1 billion) and total assets of JPY 1020.7 billion (USD 9.3 billion) in the fiscal year ending March 31, 2019.
Please visit www.teijin.com
Press Contact
Corporate Communications
Teijin Limited
+81 3 3506 4055
